ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Codexis, Inc." (CDXS) Report Updated: Sep 19, 2016 | Print This Page

Get more stock ratings by Louis Navellier

"Codexis, Inc." (CDXS)

Rating: Buy Volatility: Conservative
Total Grade: B Industry: Chemicals
Competitors: DD,SCL,CCF,ALB

Stock Analysis

Rating: Monthly View

A
B
C
D
F
September October November December January February March April May June July August

Rating: Weekly View

This Week: B down no change
Last Week: B same no change
Two Weeks Ago: B up upgrade
service keys

"Codexis, Inc."© quotemedia

Company Profile

Codexis, Inc. develops biocatalysts for the pharmaceutical and fine chemicals markets in the United States and internationally. The company offers Codex biocatalyst panels and kits to pharmaceutical companies that are engaged in drug development and the marketing of approved drugs to allow them to screen and identify possible enzymatic manufacturing processes for their drug candidates and their marketed products. It also provides enzyme screening services and enzyme optimization services; and supplies enzymes, pharmaceutical intermediates, and active pharmaceutical ingredients. In addition, the company develops biocatalysts for use in the fine chemicals market, including food, animal feed, agricultural chemicals, and flavors and fragrances. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.